Prediction of the responsiveness to antidepressants by DNA methylation in patients with major depression
| Project/Area Number |
24790541
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Hyogo University of Health Sciences |
|---|
Principal Investigator |
NONEN Shinpei 兵庫医療大学, 薬学部, 講師 (40467527)
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Project Status |
Completed (Fiscal Year 2013)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2013: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2012: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | ファーマコゲノミクス / メチル化 / うつ病 / 遺伝子多型 / DNAメチル化 / 抗うつ薬 / 個別化医療 |
|---|
| Research Abstract |
To elucidate the DNA methylation marker associated with inter-individual difference in therapeutic efficacy observed in the clinical use of antidepressants, we performed DNA methylation analysis of brain-derived neurotrophic factor (BDNF), glial cell derived neurotrophic factor (GDNF), serotonin transporter (5HTT) and Serotonin receptor 1A (5HT1A) in the patients with major depressive disorder. We first performed screening analysis of DNA methylation levels of 104 CpG sites in these 4 genes in patient with response and non-response to paroxetine. Next, in 60 patients treated with paroxetine, we investigated the association between DNA methylation level of CpG sites detected by screening analysis and efficacy of paroxetine. We detected one CpG site in BDNF gene related to response to paroxetine.
|
Report
(3 results)
Research Products
(7 results)
